Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 9,787 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 9,787 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total value of $256,419.40. Following the transaction, the executive vice president owned 138,043 shares in the company, valued at $3,616,726.60. This trade represents a 6.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Amphastar Pharmaceuticals Trading Up 1.6%

NASDAQ AMPH opened at $26.50 on Friday. The firm has a market capitalization of $1.22 billion, a PE ratio of 11.73, a P/E/G ratio of 7.31 and a beta of 0.91. The stock’s 50 day moving average is $25.55 and its 200 day moving average is $25.67. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $40.74. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.83 by $0.10. The business had revenue of $191.84 million during the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. Research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Amphastar Pharmaceuticals by 5.2% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company’s stock worth $217,000 after acquiring an additional 465 shares in the last quarter. Illumine Investment Management LLC grew its stake in Amphastar Pharmaceuticals by 2.0% in the third quarter. Illumine Investment Management LLC now owns 27,677 shares of the company’s stock valued at $738,000 after purchasing an additional 551 shares during the last quarter. Advisory Research Inc. raised its holdings in Amphastar Pharmaceuticals by 3.8% in the third quarter. Advisory Research Inc. now owns 15,468 shares of the company’s stock worth $412,000 after purchasing an additional 570 shares in the last quarter. State of Wyoming lifted its position in shares of Amphastar Pharmaceuticals by 21.2% during the third quarter. State of Wyoming now owns 3,301 shares of the company’s stock valued at $88,000 after buying an additional 578 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after buying an additional 613 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AMPH has been the subject of a number of analyst reports. Zacks Research lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Bank of America raised their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 8th. Needham & Company LLC reduced their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Barclays began coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 target price on the stock. Two analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $31.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.